 - FPI-1434 Phase 1 study is progressing - Recent transactions and partnerships expand and diversify Fusions pipeline of targeted alpha therapies in development to treat a broad array of tumor types HAMILTON, ON and BOSTON, March 25, 2021 PRNewswire -- Fusion Pharmaceuticals Inc. Nasdaq: FUSN, a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the fourth quarter ended December 31, 2020 and provided an update on clinical and corporate developments. Advancing the Phase 1 clinical study of our lead program, FPI-1434, continues to be our primary focus, said Chief Executive Officer John Valliant, Ph.D. 